Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy

Overview of attention for article published in Molecular Therapy, January 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter: 6 X users
patent: 6 patents

f1000: 1 research highlight platform

Readers on

mendeley: 65 Mendeley

So far, Altmetric has seen 6 patents that reference this research output.

TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS

Application EP-4610278-A2

European Patent Office

03 Sep 2025

Methods and compositions for treating muscular dystrophy

Application JP-2024504085-A

Japan

30 Jan 2024

COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND TARGETED SAPONIN FOR THE TREATMENT…

Application WO-2023121444-A1

World Intellectual Property Organisation (WIPO)

29 Jun 2023

COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND SAPONIN FOR THE TREATMENT OF MUSCLE-WA…

Application WO-2023121445-A1

World Intellectual Property Organisation (WIPO)

29 Jun 2023

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 2 additional patents.